vildagliptin 50mg / metformin hydrochloride 850mg film coated tablets and vildagliptin 50mg / metformin hydrochloride 1000mg film coated tablets (Eucreas® 50mg/850mg and 50mg/1000mg) (No. 477/08)

Novartis Pharmaceuticals UK Limited

Product Update

06 June 2008

The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised below

ADVICE: following an abbreviated submission

vildagliptin 50mg/metformin hydrochloride 850mg film coated tablets and vildagliptin 50mg/metformin hydrochloride 1000mg film coated tablets (Eucreas® 50mg/850mg and 50mg/1000mg) are accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.

The addition of vildagliptin to metformin is restricted to use in patients only when the addition of sulphonylureas is not appropriate, and represents an alternative to other agents such as thiazolidinediones. Efficacy, as assessed by measurement of glycated haemoglobin (HbA_{1c}), is similar to thiazolidinedione drugs added at this stage in therapy. It appears to have minimal effect on body weight.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 16 April 2008.

Chairman, Scottish Medicines Consortium

Published 7 July 2008

Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP
Telephone 0141 225 6989
E-mail: rosie.murray@nhs.net

Chairman Dr Kenneth R Paterson